Raise closed, search for fresh raises on Seedstage

Morrisville, NC

Supporting the development of a dual-action therapy for chronic respiratory diseases.

• Mission: Developing innovative therapies for chronic respiratory diseases, with a focus on addressing unmet medical needs in the respiratory therapeutics market.  
• Innovation: ALX1, a dual-action inhaled treatment targeting inflammation and infection, specifically for patients suffering from conditions like Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis.  
• Clinical Advancement: The company has received FDA clearance to begin Phase 1 clinical trials for ALX1, marking a major milestone in the development of its respiratory therapies.  
• Leadership Expertise: Vast Therapeutics boasts a seasoned leadership team with over 120 years of combined experience, including involvement in 20 FDA-approved drug applications.  
• Market Potential: Positioned to capture a share of the $90 billion global respiratory therapeutics market, addressing critical needs for patients with chronic lung conditions.  
• Strategic Partnerships: The company has secured significant funding, including investment from Shionogi & Co., Ltd., and is supported by promising preclinical data and a clear regulatory pathway.  

Vast Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for chronic respiratory diseases. The company’s lead product, ALX1, is a dual-action inhaled treatment aimed at combating inflammation and infection in the lungs, specifically targeting Pseudomonas aeruginosa, a bacterial infection prevalent in patients with diseases like Cystic Fibrosis. The company has received FDA clearance to begin Phase 1 clinical trials, marking a significant milestone in its journey to address unmet medical needs in the respiratory therapeutics market.

The funds raised through this offering will support the ongoing clinical trials for ALX1, as well as the development of additional respiratory therapies. With a strong leadership team bringing over 120 years of combined experience, including involvement in 20 FDA-approved drug applications, Vast Therapeutics is well-positioned to advance ALX1 and other therapeutic candidates. The company aims to provide much-needed solutions for patients suffering from chronic lung diseases, with the potential to capture a share of the $90 billion global respiratory therapeutics market.

Company Info

Vast Therapeutics is developing ALX1, an innovative inhaled treatment for chronic lung diseases, currently entering Phase 1 clinical trials.

Vast Therapeutics is a clinical-stage biotechnology company focused on developing therapies for chronic respiratory diseases. The company has received FDA clearance to begin Phase 1 clinical trials for its lead product candidate, ALX1, a dual-action inhaled treatment designed to address inflammation and infection, particularly targeting drug-resistant bacteria in the lungs. The company aims to address unmet needs in the $90B global respiratory therapeutics market. Vast’s experienced team brings over 120 years of combined drug development expertise, including leadership in 20 FDA-approved New Drug Applications.

ALX1 uses stabilized nitric oxide to target chronic lung conditions such as Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis, particularly focusing on patients colonized by the harmful bacteria Pseudomonas aeruginosa. The company has secured $29 million in funding to date, including a significant investment from Shionogi & Co., Ltd. With its promising preclinical data and a clear regulatory pathway, Vast Therapeutics aims to improve patient outcomes by providing new treatment options in respiratory medicine.